COVID-19 government-funded vaccination appointment system includes BNT vaccine as an option for vaccine brand preference starting August 28; AZ vaccine are available for seventh round of vaccinations and booking appointments will start at 10 a.m. on August 29


PublishTime:2021-08-28
On August 28, the Central Epidemic Command Center (CECC) pointed out that the COVID-19 vaccination registration and appointment reservation system (https://1922.gov.tw/) included the Pfizer-BioNTech (BNT) vaccine as an option for vaccine brand starting August 28 and remains open to people aged 18 and older for registration of their willingness. Regarding adolescents aged 12-17 (inclusive), vaccinations with the BNT vaccine are planned to be provided to them according to the pattern of the influenza vaccine rollout, that is, collectively given to them at schools or given to them after issuing a notice reminding them to visit healthcare facilities designated and contracted by their local health authority. Therefore, the age group is not included in this round of registration. Additionally, the available brand of vaccine in the seventh round of vaccinations is the AstraZeneca (AZ) vaccine. Scheduling a vaccination appointment on the vaccination appointment reservation system will start from 10 a.m. on August 29 to 12 p.m. on August 31.

The CECC explained that the seventh round of bookings will be open to people aged 29 and older (born on December 31, 1992, or earlier) and individuals aged 18 and older in the ninth priority group (born on September 3, 2003, or earlier), who registered their willingness to be vaccinated with the AZ vaccine before July 19, and are not vaccinated. This round of vaccinations is scheduled to take place between September 3 and September 10.

Individuals eligible to make a vaccination appointment for the AZ vaccine are reminded that they can only add the BNT vaccine to their preference after 4 p.m. on August 31 if they wish to do so. Vaccinations with a second dose of the AZ vaccine will be offered to members of the public who are eligible to receive a second dose of the vaccine after the recommended interval passed following their first shot separately from the abovementioned groups.